AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04504214 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper limb repeated multi-site tendon vibrations
Description: Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
Study NCT04504214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper limb repeated multi-site tendon vibrations
Description: Upper limb tendon vibration protocol will be added to the usual rehabilitation protocol performed during hospitalization
Study NCT02774330 — intervention group
Intervention type: OTHER
Intervention: Policy
Description: This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
Study NCT04426721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozone
Description: 10 cc of oxygen-ozone
Study NCT04426721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Description: Sinovial forte 32 mg\\2ml
Study NCT02540148 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Nova Oculus™ Micro-current electrical stimulation - Sham treatment
Description: Non-active treatment with transpalpebral micro-current electrical stimulation SHAM device, 3 sessions within 5 days of the 1st treatment. 1 session during weeks 2, 14 and 26.
Study NCT03779191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib dosed 600 mg twice a day (BID) with meals until disease progression, unacceptable toxicity, or other reasons specified in the protocol
Study NCT03779191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg intravenously every 3 weeks until disease progression, unacceptable toxicity, or other reasons specified in the protocol
Study NCT03252288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Text of phone-call based reminders to mobile phones
Study NCT03252288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conditional financial transfers
Description: Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs >1 week but within 4 weeks of the scheduled visit
Study NCT02066584 — intervention group
Intervention type: OTHER
Intervention: Sibling oocyte incubation
Study NCT02089542 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MB and fluorescent imaging
Description: Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
Study NCT00850408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
Study NCT00850408 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
Study NCT00440531 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)
Description: RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
Study NCT02382497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AN Active tDCS
Description: The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Study NCT02382497 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: AN Sham tDCS
Description: The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Study NCT02382497 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BED Active tDCS
Description: The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.~tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.~For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.~Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min.
Study NCT00440531 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Modified Process Hepatitis B Vaccine (Experimental)
Description: Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
Study NCT00440531 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ENGERIX-B™ (currently licensed product)
Description: ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
Study NCT01746342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Effective continuous positive airway pressure (CPAP)
Study NCT01746342 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham continuous positive airway pressure (CPAP)
Study NCT03358563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is a commercially marketed product that has been approved by the FDA for the treatment of metastatic prostate cancer. It is also approved for the treatment of other malignant disease, such as locally advanced or metastatic breast cancer that returns after any prior chemotherapy; locally advanced or metastatic non-small cell lung cancer that recurs after prior platinum-based chemotherapy. However, the FDA does not currently approve its use in patients with localized prostate cancer but no evidence of radiographic metastases.
Study NCT03358563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Degarelix is a leuteinizing hormone-releasing hormone (LHRH) antagonist. Degarelix is administered at an initial dose of 240 mg subcutaneously (2 separate injections of 120mg each totaling 240 mg) two weeks prior to cycle 1 day 's 1 treatment with chemotherapy. The initial dose is followed by a maintenance dose of 80mg administered subcutaneously as a single injection every 28 days at cycle 2 day 1 (+/- 7 days) and cycle 3 day 10 (+/- 7 days)
Study NCT03358563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: The dose for bicalutamide tablets therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening), with or without food. It is recommended that bicalutamide tablets be taken at the same time each day. Treatment with bicalutamide tablets should be started at the same time as treatment with an LHRH analog.
Study NCT03358563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ferumoxytol-enhanced MRI imaging
Description: Ferumoxytol-enhanced MRI imaging will evaluate immune micro-environment in the prostate. Three subjects enrolled to the study will undergo the first ferumoxytol-enhanced MRI imaging within 21 days prior to start of hormonal therapy followed by second and final ferumoxytol-enhanced MRI at the conclusion of hormone therapy but prior to their prostatectomy.
Study NCT02382497 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BED Sham tDCS
Description: The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
Study NCT04554810 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication Management Service
Description: Medication review was delivered to the Syrian refugees by accredited pharmacists at the baseline visit. This followed by identifying the treatment-related problems (TRP) by the clinical pharmacist, and correction of the approved TRPs by the corresponding physicians and finally convey these changes in medications to the patients. In addition, counselling and education were delivered to the refugees' patients in the base line visit.
Study NCT00077142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC-101
Description: Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
Study NCT04437251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
Study NCT02972684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombo-elastometry POC testing
Description: Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
Study NCT01798810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supplemental Perioperative Oxygen
Description: Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
Study NCT02148757 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Doppler Ultrasound
Study NCT02055989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose-escalated radiotherapy level 1
Study NCT02055989 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sequential dose-escalated radiotherapy level 2
Study NCT04437251 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation (tDCS) is an non-invasive, low-intensity direct current stimulation. The stimulation intensity is very low (0- 2 mA) to only produce tingling sensation on the scalp. From literature, there were no serious adverse effects reported after 20-minute stimulation. The main temporary side effect is skill irritation, itching sensation at the stimulation site during or after stimulation.
Study NCT04616508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor control assessment
Description: Basic science study of control of reaching movements
Study NCT01394965 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: ECG electrodes
Description: Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
Study NCT01562782 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fructose + Glucose Beverage
Description: Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
Study NCT01562782 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose + Glucose Beverage
Description: Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
Study NCT03149432 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
Study NCT02807896 — intervention group
Intervention type: OTHER
Description: This study is cohort.
Study NCT02062268 — intervention group
Intervention type: BEHAVIORAL
Intervention: health education & law enforcement
Study NCT02245932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 4 weeks of 150 mg resveratrol (2 times 75mg/day)
Study NCT02245932 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 weeks of placebo supplementation (two doses per day)
Study NCT03151005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin-GLP-1 Receptor Agonist
Description: metformin oral with exenatide/liraglutide subcutaneous injection.
Study NCT03151005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin-Oral Contraceptive(OC)
Description: metformin with Diane 35 oral intake.
Study NCT03339674 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Group Intervention on Alcohol Drinking Related to Stress
Description: Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
Study NCT03339674 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Training
Description: Manualized and standardized psychotherapeutic group intervention with three sessions of 60 min duration each which are to be delivered in a one-week period.
Study NCT00156065 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: 2-8 mg BID
Study NCT00156065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 or 10 mg BID
Study NCT04473131 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Only blood samples will be taken from participants for this study
Study NCT03115983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LimiFlex
Description: LimiFlex implantation at a single level after surgical decompression.
Study NCT03115983 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion Instrumentation
Description: Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only), and/or a synthetic bone graft extender that is on-label for these indications (i.e., decorticated posterolateral gutter only). The TLIF requires a single PEEK or Titanium TLIF cage cleared by FDA for this indication filled with autograft and/or allograft bone (i.e., cancellous and/or corticocancellous bone only).
Study NCT03115983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Decompression
Description: Surgical decompression at one or two contiguous levels from L1 to S1.
Study NCT03115983 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decompression
Description: Surgical decompression at one or two contiguous levels from L1 to S1.
Study NCT03386097 — intervention group
Intervention type: OTHER
Intervention: Collection of interstitial fluid, skin biopsies and blood
Description: Collection of interstitial fluid, skin biopsies and blood
Study NCT01934374 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task-Oriented Lower Extremity Strengthening Training
Description: On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.~The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity.
Study NCT03890250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
Study NCT03890250 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Aerobic exercise
Description: A 20-30 minutes low-medium intensity aerobic exercise training with cycling ergometer.
Study NCT03890250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Bilateral NMES application on Quadriceps femoris muscle will be applied as symmetrical biphasic square wave current with a wave frequency of 35-60 Hz, phase transition time of 8 seconds and active resting time of 15 seconds
Study NCT03091166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Study NCT02523365 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interventional therapy
Description: cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT02523365 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: interventional therapy
Description: cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
Study NCT04780503 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Rapid Shallow Breathing Index
Description: The RSBI is defined as the ratio of respiratory frequency to tidal volume.
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.25 g PA21 (250 mg iron)
Description: Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5.0 g PA21 (1,000 mg iron)
Description: Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7.5 g PA21 (1,500 mg iron)
Description: Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10.0 g PA21 (2,000 mg iron)
Description: Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12.5 g PA21 (2,500 mg iron)
Description: Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
Study NCT00824460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Description: Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
Study NCT03982849 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone 4% Cream
Description: Hydroquinone is tyrosinase inhibitor and thus inhibits melanogenesis.
Study NCT02882217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XC8 (histamine glutarimide)
Study NCT02882217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03982849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: silymarin 0.7% cream
Description: Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
Study NCT03115983 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion
Description: Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
Study NCT00175825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
Study NCT00175825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Daily oral dose of two equal intakes, morning and evening, of Brivaracetam over the 7-week Treatment Period
Study NCT03952858 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Group
Description: The telerehabilitation Group receives physiotherapy supervised exercises on-line. The Community Center Group receives the traditionel training offer in the municipality Center for older people.